IRIS
Trivellin, Giampaolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.082
AS - Asia 1.731
EU - Europa 447
SA - Sud America 322
Continente sconosciuto - Info sul continente non disponibili 97
AF - Africa 44
OC - Oceania 11
Totale 4.734
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.986
SG - Singapore 994
CN - Cina 397
BR - Brasile 268
VN - Vietnam 148
IT - Italia 80
FI - Finlandia 59
IE - Irlanda 59
CA - Canada 56
GB - Regno Unito 50
DE - Germania 38
HK - Hong Kong 36
FR - Francia 28
IN - India 28
RU - Federazione Russa 27
AR - Argentina 24
JP - Giappone 24
MX - Messico 19
BE - Belgio 16
BD - Bangladesh 15
CZ - Repubblica Ceca 13
ES - Italia 13
PK - Pakistan 13
ID - Indonesia 12
AU - Australia 11
SE - Svezia 11
IQ - Iraq 10
ZA - Sudafrica 10
AT - Austria 9
NL - Olanda 9
PL - Polonia 9
VE - Venezuela 9
EC - Ecuador 7
UZ - Uzbekistan 7
DZ - Algeria 6
JM - Giamaica 6
MA - Marocco 6
PH - Filippine 6
TR - Turchia 6
AZ - Azerbaigian 5
CH - Svizzera 5
CL - Cile 5
TN - Tunisia 5
UA - Ucraina 5
CO - Colombia 4
DO - Repubblica Dominicana 4
EG - Egitto 4
NP - Nepal 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CI - Costa d'Avorio 3
HN - Honduras 3
HU - Ungheria 3
KE - Kenya 3
KG - Kirghizistan 3
MY - Malesia 3
UY - Uruguay 3
ET - Etiopia 2
GT - Guatemala 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
MD - Moldavia 2
NG - Nigeria 2
NO - Norvegia 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
BB - Barbados 1
BZ - Belize 1
CR - Costa Rica 1
DK - Danimarca 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
MR - Mauritania 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 4.637
Salva come PNG Salva come JPEG
Città #
Singapore 447
San Jose 294
Ashburn 213
Shanghai 194
The Dalles 163
Dallas 104
New York 94
Council Bluffs 89
Beijing 84
Boardman 82
Los Angeles 65
Dublin 59
Helsinki 58
Santa Clara 55
Ho Chi Minh City 50
Hong Kong 31
Milan 31
Hanoi 29
São Paulo 27
Buffalo 22
Phoenix 21
Seattle 20
Houston 18
Gatineau 16
Liège 15
Moscow 15
Chicago 14
Brno 12
Brooklyn 12
Montreal 12
Rio de Janeiro 11
Atlanta 10
Boston 10
Melbourne 10
Tokyo 10
Toronto 10
Johannesburg 9
Stockholm 9
Chandler 8
Charlotte 8
Lahore 8
Manchester 8
Orem 8
Rome 8
Da Nang 7
Denver 6
London 6
Milwaukee 6
Munich 6
Naples 6
San Francisco 6
Tashkent 6
Vienna 6
Washington 6
Abbeville 5
Baghdad 5
Baku 5
Belo Horizonte 5
Curitiba 5
Eustis 5
Guarulhos 5
Haiphong 5
Miami 5
Newark 5
Porto Alegre 5
Princeton 5
Southwark 5
Warsaw 5
Assago 4
Birmingham 4
Buenos Aires 4
Can Tho 4
Chennai 4
Columbus 4
Fortaleza 4
Frankfurt am Main 4
Higashiosaka 4
Hải Dương 4
Mexico City 4
Nashville 4
New Delhi 4
Oklahoma City 4
Philadelphia 4
Quito 4
San Diego 4
St Petersburg 4
São José dos Campos 4
Abidjan 3
Amsterdam 3
Bishkek 3
Bến Tre 3
Campinas 3
Caxias do Sul 3
Figino 3
Guayaquil 3
Hangzhou 3
Juiz de Fora 3
Kingston 3
Kuala Lumpur 3
La Marque 3
Totale 2.719
Salva come PNG Salva come JPEG
Nome #
Use of G protein-coupled receptor 101 inhibitor, antagonist or inverse agonist for prevention and/or therapeutic treatment of diseases selected from group consisting of acromegaly and gigantism 179
Characterization of GPR101: Transcripts Structure, Expression Pattern, and Signal Transduction Pathways 152
Alteration of the immunophenotype and cytokine profiles in patients affected by neuroendocrine neoplasms 111
Case Report: New CDKN1B Mutation in Multiple Endocrine Neoplasia Type 4 and Brief Literature Review on Clinical Management 101
Characterization of GPR101 Expression Across Different Species 93
Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia 83
X-Linked Acro-Gigantism (X-LAG) Due to Microduplications of Chromosome Xq26: A New Disorder and Implications for Acromegaly 81
X-linked acro-gigantism (X-LAG): a new form of infant-onset pituitary gigantism 80
Filamin A is involved in human intrahepatic cholangiocarcinoma aggressiveness and progression 75
An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations 73
A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred 73
Characterization of GPR101 transcript structure and expression patterns 72
Comparing models and experimental structures of the GPR101 receptor: Artificial intelligence yields highly accurate models 71
Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess 71
miR-107 inhibits the expression of aryl hydrocarbon receptor interacting protein (AIP) and is potentially involved in pituitary tumorigenesis 70
FAF1 Gene Involvement in Pituitary Corticotroph Tumors 69
CD40LG duplications in patients with X-LAG syndrome commonly undergo random X-chromosome inactivation 68
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion 68
The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors 68
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers 67
Xq26.3 Duplication in a Boy With Motor Delay and Low Muscle Tone Refines the X-Linked Acrogigantism Genetic Locus 65
Chaperones, somatotroph tumors and the cyclic AMP (cAMP)-dependent protein kinase (PKA) pathway 65
AIP and its interacting partners 65
Germline mutations in a G protein identify signaling cross-talk in T cells 65
Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus 65
GPR101: Modeling a constitutively active receptor linked to X-linked acrogigantism 63
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors 61
Characterization of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutations in Familial Isolated Pituitary Adenoma Families 60
PAM variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomas 59
Characterization of the adiponectin promoter + Cre recombinase insertion in the Tg(Adipoq-cre)1Evdr mouse by targeted locus amplification and droplet digital PCR 59
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 58
Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland 58
Interaction of AIP with protein kinase A (cAMP-dependent protein kinase) 57
Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up 57
AIP Mutation in Pituitary Adenomas REPLY 55
Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease 55
Genetics of gigantism and acromegaly 55
Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations 54
A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype 54
Increased expression of miR-34a explains the low AIP protein level present in 50% of sporadic somatotropinomas 53
Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants 53
Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome 53
Evaluation of CDKN1B germline mutations in a cohort of acromegalic patients with evidences of multiple neoplasia 53
Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism 53
Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly? 52
The direct impact of pegvisomant on osteoblast functions and bone development 51
MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro 51
Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal alpha-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition 51
The Glucose-Dependent Insulinotropic Polypeptide Receptor is Overexpressed Amongst GNAS1 Mutation-Negative Somatotropinomas and Drives Growth Hormone (GH)-Promoter Activity in GH3 Cells 49
MicroRNAs: Suggested role in pituitary adenoma pathogenesis 49
Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's disease 48
Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway 47
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 47
SATB1: a gene involved in pituitary development may have a role in somatotroph tumors 46
Evaluation of p27KIP1 germline mutations in familial phaeochromocytoma and clinically suspected MEN1 patients 46
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study 45
Evaluation of mutations in aryl hydrocarbon receptor interacting protein (AIP) in acromegalic sporadic cases and in one FIPA family 45
Hereditary endocrine tumours: Current state-of-the-art and research opportunities: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis 44
Oncogene-induced senescence in pituitary adenomas and carcinomas 44
GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency 44
The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish 44
Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers 44
Diagnosis and Treatment of Parasellar Lesions 42
Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients 42
Large genomic aberrations in corticotropinomas are associated with greater aggressiveness 42
Familial pituitary apoplexy as the only presentation of a novel AIP mutation 41
Gigantism, Acromegaly, and GPR101 Mutations REPLY 41
Stable GPR101 over-expressing cell lines as an invaluable tool for functional studies, ligand screening, and the identification of deregulated genes/pathways in patients with X-linked acrogigantism 41
Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation 40
Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic Investigation 40
Genetics, clinical features and outcomes of non-syndromic pituitary gigantism: experience of a single center from Sao Paulo, Brazil 40
Screening for GPR101 defects in pediatric pituitary corticotropinomas 39
Prkar1a haploinsufficiency ameliorates the growth hormone excess phenotype in Aip-deficient mice 39
MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics 38
Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas 37
GHRH excess and blockade in X-LAG syndrome 37
Familial isolated pituitary adenomas: An emerging clinical entity 37
Is IGSF1 involved in human pituitary tumor formation? 36
Pituitary gigantism: update on molecular biology and management 35
IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction 34
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 33
Hereditary endocrine tumours: Current state-of-the-art and research opportunities: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA) 33
Totale 4.734
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.702
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.702
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202210 0 0 0 0 0 0 0 0 1 4 4 1
2022/202396 4 2 2 2 3 2 0 1 6 4 0 70
2023/2024706 50 31 145 21 36 80 90 50 13 24 61 105
2024/2025952 37 4 18 15 11 139 113 54 94 220 129 118
2025/20262.318 321 143 120 234 131 129 622 116 113 143 114 132
2026/2027652 69 128 386 69 0 0 0 0 0 0 0 0
Totale 4.734